MX339899B - Compuestos de triazolopiridina como inhibidores de pim cinasa. - Google Patents

Compuestos de triazolopiridina como inhibidores de pim cinasa.

Info

Publication number
MX339899B
MX339899B MX2013009820A MX2013009820A MX339899B MX 339899 B MX339899 B MX 339899B MX 2013009820 A MX2013009820 A MX 2013009820A MX 2013009820 A MX2013009820 A MX 2013009820A MX 339899 B MX339899 B MX 339899B
Authority
MX
Mexico
Prior art keywords
pim
compounds
triazolopiridine
cinasa
inhibitors
Prior art date
Application number
MX2013009820A
Other languages
English (en)
Spanish (es)
Other versions
MX2013009820A (es
Inventor
Wang Bin
F Blake James
Kirk Delisle Robert
A De Meese Lisa
m graham James
Le Huerou Yvan
Lyon Michael
e robinson John
M Wallace Eli
Xu Rui
Original Assignee
Array Biopharma Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Array Biopharma Inc filed Critical Array Biopharma Inc
Publication of MX2013009820A publication Critical patent/MX2013009820A/es
Publication of MX339899B publication Critical patent/MX339899B/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
    • C07D471/04—Ortho-condensed systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/4353—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems
    • A61K31/437—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems the heterocyclic ring system containing a five-membered ring having nitrogen as a ring hetero atom, e.g. indolizine, beta-carboline
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/02—Drugs for dermatological disorders for treating wounds, ulcers, burns, scars, keloids, or the like
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/06—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
    • C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
    • C07D487/04—Ortho-condensed systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
    • C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
    • C07D487/10—Spiro-condensed systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D491/00—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00
    • C07D491/02—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00 in which the condensed system contains two hetero rings
    • C07D491/04—Ortho-condensed systems
    • C07D491/044—Ortho-condensed systems with only one oxygen atom as ring hetero atom in the oxygen-containing ring
    • C07D491/048—Ortho-condensed systems with only one oxygen atom as ring hetero atom in the oxygen-containing ring the oxygen-containing ring being five-membered
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D519/00—Heterocyclic compounds containing more than one system of two or more relevant hetero rings condensed among themselves or condensed with a common carbocyclic ring system not provided for in groups C07D453/00 or C07D455/00

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Immunology (AREA)
  • Rheumatology (AREA)
  • Dermatology (AREA)
  • Neurology (AREA)
  • Pain & Pain Management (AREA)
  • Biomedical Technology (AREA)
  • Transplantation (AREA)
  • Neurosurgery (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Pulmonology (AREA)
  • Epidemiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
  • Plural Heterocyclic Compounds (AREA)
MX2013009820A 2011-02-25 2012-02-24 Compuestos de triazolopiridina como inhibidores de pim cinasa. MX339899B (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201161446902P 2011-02-25 2011-02-25
PCT/US2012/026572 WO2012154274A1 (en) 2011-02-25 2012-02-24 Triazolopyridine compounds as pim kinase inhibitors

Publications (2)

Publication Number Publication Date
MX2013009820A MX2013009820A (es) 2014-09-01
MX339899B true MX339899B (es) 2016-06-16

Family

ID=46000320

Family Applications (1)

Application Number Title Priority Date Filing Date
MX2013009820A MX339899B (es) 2011-02-25 2012-02-24 Compuestos de triazolopiridina como inhibidores de pim cinasa.

Country Status (32)

Country Link
US (1) US8889704B2 (OSRAM)
EP (1) EP2678329B1 (OSRAM)
JP (2) JP6039585B2 (OSRAM)
KR (1) KR101940338B1 (OSRAM)
CN (1) CN103492377B (OSRAM)
AR (1) AR085489A1 (OSRAM)
AU (1) AU2012254082B2 (OSRAM)
BR (1) BR112013021675A2 (OSRAM)
CA (1) CA2828269C (OSRAM)
CL (1) CL2013002446A1 (OSRAM)
CO (1) CO6771441A2 (OSRAM)
CR (1) CR20130460A (OSRAM)
CY (1) CY1117197T1 (OSRAM)
DK (1) DK2678329T3 (OSRAM)
ES (1) ES2563152T3 (OSRAM)
HR (1) HRP20160134T1 (OSRAM)
HU (1) HUE027675T2 (OSRAM)
IL (1) IL228108A (OSRAM)
ME (1) ME02365B (OSRAM)
MX (1) MX339899B (OSRAM)
PH (1) PH12013501754A1 (OSRAM)
PL (1) PL2678329T3 (OSRAM)
RS (1) RS54586B1 (OSRAM)
RU (1) RU2598846C2 (OSRAM)
SG (1) SG192944A1 (OSRAM)
SI (1) SI2678329T1 (OSRAM)
SM (1) SMT201600052B (OSRAM)
TW (1) TWI529170B (OSRAM)
UA (1) UA111075C2 (OSRAM)
UY (1) UY33924A (OSRAM)
WO (1) WO2012154274A1 (OSRAM)
ZA (1) ZA201306997B (OSRAM)

Families Citing this family (22)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP6105578B2 (ja) 2011-07-21 2017-03-29 トレロ ファーマシューティカルズ， インコーポレイテッド 複素環式プロテインキナーゼ阻害剤
CN104203915B (zh) * 2012-04-25 2017-03-08 霍夫曼-拉罗奇有限公司 (3，4‑二氯‑苯基)‑((s)‑3‑丙基‑吡咯烷‑3‑基)‑甲酮盐酸盐和制造方法
WO2014110574A1 (en) 2013-01-14 2014-07-17 Incyte Corporation Bicyclic aromatic carboxamide compounds useful as pim kinase inhibitors
RS60244B1 (sr) 2013-01-15 2020-06-30 Incyte Holdings Corp Jedinjenja tiazolkarboksamida i piridinkarboksamida korisna kao inhibitori pim kinaze
WO2015027124A1 (en) 2013-08-23 2015-02-26 Incyte Corporation Furo- and thieno-pyridine carboxamide compounds useful as pim kinase inhibitors
WO2016010897A1 (en) 2014-07-14 2016-01-21 Incyte Corporation Bicyclic heteroaromatic carboxamide compounds useful as pim kinase inhibitors
US9580418B2 (en) 2014-07-14 2017-02-28 Incyte Corporation Bicyclic aromatic carboxamide compounds useful as Pim kinase inhibitors
US9540347B2 (en) 2015-05-29 2017-01-10 Incyte Corporation Pyridineamine compounds useful as Pim kinase inhibitors
AR105967A1 (es) 2015-09-09 2017-11-29 Incyte Corp Sales de un inhibidor de pim quinasa
US9920032B2 (en) 2015-10-02 2018-03-20 Incyte Corporation Heterocyclic compounds useful as pim kinase inhibitors
CN115028617A (zh) * 2016-05-24 2022-09-09 基因泰克公司 Cbp/ep300的杂环抑制剂及其在治疗癌症中的用途
AR113922A1 (es) 2017-12-08 2020-07-01 Incyte Corp Terapia de combinación de dosis baja para el tratamiento de neoplasias mieloproliferativas
CN112236139A (zh) 2018-04-13 2021-01-15 大日本住友制药肿瘤公司 用于治疗骨髓增殖性肿瘤和与癌症相关的纤维化的pim激酶抑制剂
WO2020017569A1 (ja) 2018-07-17 2020-01-23 日本ケミファ株式会社 Ｔ型カルシウムチャネル阻害剤
CN108912032A (zh) * 2018-08-13 2018-11-30 南通大学 一种（3s，4r）-4-甲基吡咯烷-3-基氨基甲醇叔丁酯盐酸盐的化学合成方法
CN109053526A (zh) * 2018-08-13 2018-12-21 南通大学 一种（3r，4s）-4-甲基吡咯烷-3-基氨基甲酸叔丁酯盐酸盐的化学合成方法
WO2020157709A1 (en) 2019-02-01 2020-08-06 Pfizer Inc. Combination of a cdk inhibitor and a pim inhibitor
JP7662528B2 (ja) 2019-02-12 2025-04-15 スミトモ ファーマ アメリカ， インコーポレイテッド 複素環式タンパク質キナーゼ阻害剤を含む製剤
US20220056043A1 (en) * 2019-02-19 2022-02-24 Sichuan Kelun-Biotech Biopharmaceutical Co., Ltd. Nitrogen-containing fused cyclic compound, preparation method therefor and use thereof
AU2020250468A1 (en) 2019-03-29 2021-11-04 Kinki University Use of T-type calcium channel blocker for treating pruritus
CN111171023B (zh) * 2020-01-10 2021-12-21 中国药科大学 一种具有Pim1抑制活性的化合物及其制备方法与医药用途
EP4611753A1 (en) 2022-10-31 2025-09-10 Sumitomo Pharma America, Inc. Pim1 inhibitor for treating myeloproliferative neoplasms

Family Cites Families (25)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ES2195943T3 (es) 1999-11-12 2003-12-16 Neurogen Corp Compuestos heteroaromaticos biciclicos y triciclicos.
UA75055C2 (uk) * 1999-11-30 2006-03-15 Пфайзер Продактс Інк. Похідні бензоімідазолу, що використовуються як антипроліферативний засіб, фармацевтична композиція на їх основі
AU2001252609A1 (en) 2000-04-27 2001-11-12 Imperial Cancer Research Technology Ltd. Imidazopyridine derivatives
DE10038019A1 (de) 2000-08-04 2002-02-14 Bayer Ag Substituierte Triazolopyrid(az)ine
CN1496366A (zh) 2001-03-09 2004-05-12 �Ʒ� 作为抗炎剂的三唑并吡啶
US7227006B2 (en) 2002-01-19 2007-06-05 Sanofi-Aventis Deutschland Gmbh PIM-3 kinase as a target for type 2 diabetes mellitus
DE60326646D1 (de) 2002-12-18 2009-04-23 Vertex Pharma Benzisoxazolderivate, die sich als inhibitoren von proteinkinasen eigen
EP1575959B1 (en) 2002-12-18 2010-07-14 Vertex Pharmaceuticals Incorporated Compositions useful as inhibitors of protein kinases
US20050164300A1 (en) 2003-09-15 2005-07-28 Plexxikon, Inc. Molecular scaffolds for kinase ligand development
US20050256309A1 (en) 2004-05-12 2005-11-17 Altenbach Robert J Tri-and bi-cyclic heteroaryl histamine-3 receptor ligands
JP2008509985A (ja) 2004-08-18 2008-04-03 ファルマシア アンド アップジョン カンパニー リミテッド ライアビリティ カンパニー 炎症治療用の新規トリアゾロピリジン化合物
AU2005311451A1 (en) 2004-12-01 2006-06-08 Merck Serono Sa [1,2,4]triazolo[4,3-a]pyridine derivatives for the treatment of hyperproliferative diseases
WO2007044724A2 (en) 2005-10-06 2007-04-19 Exelixis, Inc. Aminopyrimidine, aminopyridine and aniline derivatives inhibitors of pim-i and/or pim-3
CA2636043A1 (en) 2006-01-23 2007-08-02 Amira Pharmaceuticals, Inc. Tricyclic inhibitors of 5-lipoxygenase
MX2008015747A (es) 2006-06-06 2008-12-19 Schering Corp Imidazopirazinas como inhibidores de la proteina quinasa.
MY146474A (en) 2006-11-06 2012-08-15 Supergen Inc Imidazo[1,2-b]pyridazine and pyrazolo[1,5-a]pyrimidine derivatives and their use as protein kinase inhibitors
WO2008082839A2 (en) 2006-12-29 2008-07-10 Abbott Laboratories Pim kinase inhibitors as cancer chemotherapeutics
CA2679809A1 (en) * 2007-03-02 2008-09-12 Schering Corporation Benzimidazole derivatives and methods of use thereof
JP2010522765A (ja) * 2007-03-28 2010-07-08 アレイ バイオファーマ、インコーポレイテッド 受容体チロシンキナーゼとしてのイミダゾ［１，２−ａ］ピリジン化合物
HRP20130660T1 (en) * 2007-04-03 2013-08-31 Array Biopharma, Inc. Imidazo[1,2-a]pyridine compounds as receptor tyrosine kinase inhibitors
CL2009001152A1 (es) 2008-05-13 2009-10-16 Array Biopharma Inc Compuestos derivados de n-(4-(cicloalquilo nitrogenado-1-il)-1h-pirrolo[2,3-b]piridin-3-il)amida, inhibidores de cinasa; proceso de preparacion; composicion farmaceutica; y su uso para el tratamiento de una enfermedad proliferativa.
US8557809B2 (en) 2008-08-19 2013-10-15 Array Biopharma Inc. Triazolopyridine compounds as PIM kinase inhibitors
TWI496779B (zh) 2008-08-19 2015-08-21 Array Biopharma Inc 作為ｐｉｍ激酶抑制劑之三唑吡啶化合物
US20110184013A1 (en) * 2008-10-01 2011-07-28 Shelley Allen Imidazo[1,2-a]Pyridine Compounds As Receptor Tyrosine Kinase Inhibitors
EP2410857B1 (en) * 2009-03-23 2014-01-29 Merck Sharp & Dohme Corp. P2x3, receptor antagonists for treatment of pain

Also Published As

Publication number Publication date
TWI529170B (zh) 2016-04-11
RS54586B1 (sr) 2016-08-31
NZ615300A (en) 2014-12-24
SI2678329T1 (sl) 2016-05-31
AU2012254082A1 (en) 2013-09-26
CY1117197T1 (el) 2017-04-05
WO2012154274A1 (en) 2012-11-15
UA111075C2 (uk) 2016-03-25
ES2563152T3 (es) 2016-03-11
IL228108A (en) 2017-07-31
HRP20160134T1 (hr) 2016-04-08
IL228108A0 (en) 2013-09-30
AU2012254082B2 (en) 2016-12-08
CL2013002446A1 (es) 2014-04-11
CA2828269A1 (en) 2012-11-15
HK1190714A1 (zh) 2014-07-11
CR20130460A (es) 2013-10-16
KR101940338B1 (ko) 2019-01-18
RU2013143292A (ru) 2015-04-10
SMT201600052B (it) 2016-04-29
BR112013021675A2 (pt) 2016-11-01
CA2828269C (en) 2019-01-15
AR085489A1 (es) 2013-10-09
JP2016106118A (ja) 2016-06-16
ME02365B (me) 2016-06-20
EP2678329A1 (en) 2014-01-01
CN103492377B (zh) 2016-04-20
JP2014509322A (ja) 2014-04-17
CN103492377A (zh) 2014-01-01
HUE027675T2 (en) 2016-11-28
DK2678329T3 (da) 2016-02-22
MX2013009820A (es) 2014-09-01
EP2678329B1 (en) 2015-11-18
KR20140021577A (ko) 2014-02-20
CO6771441A2 (es) 2013-10-15
PL2678329T3 (pl) 2016-06-30
US20140005213A1 (en) 2014-01-02
ZA201306997B (en) 2015-05-27
SG192944A1 (en) 2013-09-30
UY33924A (es) 2013-09-30
PH12013501754A1 (en) 2013-10-14
RU2598846C2 (ru) 2016-09-27
TW201245193A (en) 2012-11-16
JP6039585B2 (ja) 2016-12-07
US8889704B2 (en) 2014-11-18

Similar Documents

Publication Publication Date Title
MX339899B (es) Compuestos de triazolopiridina como inhibidores de pim cinasa.
EA201201648A1 (ru) Стимуляторы sgc
BR112012007747A2 (pt) Compostos heterocíclicos úteis como inibidores de pdk1, sua composição farmacêutica e seus usos
EA201590748A1 (ru) Противовирусные соединения против rsv
MX366318B (es) Derivados de aminas heterocíclicas que inhiben la transducción de señal mediana por cinasa asociada con el receptor de interleucina-1.
TR201813877T4 (tr) Spi̇nal müsküler atrofi̇ni̇n tedavi̇ edi̇lmesi̇ne yöneli̇k bi̇leşi̇kler.
TN2012000578A1 (en) Tetrahydro-pyrido-pyrimidine derivatives
EA201590005A1 (ru) Замещенные трициклические соединения как ингибиторы fgfr
CR20120510A (es) Derivados de piperidin-4-il azetidina como inhibidores de jak1
UY34472A (es) Derivados modificados de 4-fenil-piridina
EA201491766A1 (ru) Соединения для лечения спинальной мышечной атрофии
EA201071320A1 (ru) Активаторы глюкокиназы
EA201270257A1 (ru) Производные n1-сульфонил-5-фторпиримидинона
CU24097B1 (es) Compuestos piridiloxi-indoles sustituidos como inhibidores del vegf-r2 útiles para el tratamiento de enfermedades proliferativas
EA201491412A1 (ru) Соединения для лечения спинальной мышечной атрофии
MX348451B (es) Derivados de n-[(1h-pirazol-1-il)aril]-1h-indol o 1h-indazol-3-carboxamida, su preparación y su uso como antagonistas p2y12.
SV2011003855A (es) Heteroarilos sustituidos
IN2014CN03597A (OSRAM)
IN2015DN01151A (OSRAM)
MA32723B1 (fr) Derives d'anilino-pyrimidine a substitution sulfoximine en tant qu'inhibiteurs de cdk, leur preparation et leur utilisation comme medicaments
GEP20166489B (en) 1h-indazole-3-carboxamide compounds as glycogen synthase kinase 3 beta inhibitors
EA201591024A1 (ru) Димерные соединения
UY34314A (es) Derivados de anilina, su preparación y su aplicación terapéutica.
UA106889C2 (uk) Похідні n1-ацил-5-фторпіримідинону
CR20130610A (es) Método de tratamiento de la fiebre dengue

Legal Events

Date Code Title Description
FG Grant or registration